CCR5 antagonists: host-targeted antivirals for the treatment of HIV infectionWESTBY, Mike; VAN DER RYST, Elna.Antiviral chemistry & chemotherapy. 2005, Vol 16, Num 6, pp 339-354, issn 0956-3202, 16 p.Article

Consent for participation in the Bloemfontein vitamin A trial: How informed and voluntary?JOUBERT, Gina; STEINBERG, Hannes; VAN DER RYST, Elna et al.American journal of public health (1971). 2003, Vol 93, Num 4, pp 582-584, issn 0090-0036, 3 p.Article

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maravirocROSARIO, Maria C; POLAND, Bill; SULLIVAN, John et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 42, Num 2, pp 183-191, issn 1525-4135, 9 p.Article

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maravirocROSARIO, Maria C; JACQMIN, Philippe; DORR, Pat et al.Clinical pharmacology and therapeutics. 2005, Vol 78, Num 5, pp 508-519, issn 0009-9236, 12 p.Article

HIV/AIDS-related knowledge, attitudes and practices among South African military recruitsVAN DER RYST, Elna; JOUBERT, Gina; STEYN, Francois et al.SAMJ. South African medical journal. 2001, Vol 91, Num 7, pp 587-591, issn 0256-9574Article

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteersABEL, Samanta; VAN DER RYST, Elna; ROSARIO, Maria C et al.British journal of clinical pharmacology. 2008, Vol 65, pp 5-18, issn 0306-5251, 14 p., SUP1Article

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsCOOPER, David A; HEERA, Jayvant; SAAG, Michael et al.AIDS (London). 2014, Vol 28, Num 5, pp 717-725, issn 0269-9370, 9 p.Article

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patientsROSARIO, Maria C; JACQMIN, Philippe; DORR, Pat et al.British journal of clinical pharmacology. 2008, Vol 65, pp 86-94, issn 0306-5251, 9 p., SUP1Article

Hepatic safety and tolerability in the maraviroc clinical development programAYOUB, Ayman; ALSTON, Sam; GOODRICH, James et al.AIDS (London). 2010, Vol 24, Num 17, pp 2743-2750, issn 0269-9370, 8 p.Article

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1SAAG, Michael; GOODRICH, James; FÄTKENHEUER, Gerd et al.The Journal of infectious diseases. 2009, Vol 199, Num 11, pp 1638-1647, issn 0022-1899, 10 p.Article

Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoirWESTBY, Mike; LEWIS, Marilyn; WHITCOMB, Jeannette et al.Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, issn 0022-538X, 12 p.Article

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 InfectionCOOPER, David A; HEERA, Jayvant; REEVES, Jacqueline D et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 803-813, issn 0022-1899, 11 p.Article

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 InfectionFÄTKENHEUER, Gerd; NELSON, Mark; BELLOS, Nicholaos et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1442-1455, issn 0028-4793, 14 p.Article

Baseline CD4⁺ T―cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment―experienced patientsSCHAPIRO, Jonathan M; BOUCHER, Charles Ab; PERROS, Manos et al.Antiviral therapy (London). 2011, Vol 16, Num 3, pp 395-404, issn 1359-6535, 10 p.Article

Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionGULICK, Roy M; LALEZARI, Jacob; MONTANA, John B et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1429-1441, issn 0028-4793, 13 p.Article